given as a subcutaneous injection. Dupixent is a biologic and belongs to a drug class called interleukin-4 (IL-4) receptor blockers. The medication is not available in a biosimilar version.

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Marketed Products Regeneron is progressing numerous promising drug candidates ... 12 years of age, DUPIXENT should be given by a caregiver. EYLEA HD ® (aflibercept) Injection 8 mg is a ...

This includes medicated creams and pills, dupilumab (Dupixent ... not improved with topical drugs. If people have Original Medicare, Part B covers phototherapy and injection treatments for ...

The IL-4 and IL-13 targeting antibody is administered as a subcutaneous injection ... of Dupixent, having begun the process in August. Based on previous timelines for similar drugs, Sanofi may ...

These drugs inhibit interleukin (IL)-5, while Dupixent inhibits IL-4 and IL-13, but can be considered a rival because it is also an injection. Patients may opt to take the others because of their ...

We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, we are going to take a look ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Looking at Q4 on Slide 6, we reported double-digits sales growth for a third consecutive quarter, supported by our key drivers, vaccines Dupixent ... a few weeks after injection, and we know ...